



CONTACT:  
Charles Robb  
Chief Financial Officer  
Corcept Therapeutics  
650-688-8783  
[crobb@corcept.com](mailto:crobb@corcept.com)  
[www.corcept.com](http://www.corcept.com)

**CORCEPT THERAPEUTICS TO ANNOUNCE THIRD QUARTER FINANCIAL RESULTS, PROVIDE CORPORATE UPDATE AND HOST CONFERENCE CALL**

**MENLO PARK, Calif.**, (October 26, 2017) – Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report its third quarter 2017 financial results and provide a corporate update on November 2, 2017. The Company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).

**Conference Call Information**

To participate, dial 1-888-771-4371 from the United States or 1-847-585-4405 internationally approximately 10 minutes before the start of the call. The passcode is 45799161.

A replay will be available through November 16, 2017 at 1-888-843-7419 from the United States and 1-630-652-3042 internationally. The passcode will be 45799161.

**About Corcept Therapeutics Incorporated**

Corcept is a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol. Korlym® (mifepristone), a first-generation cortisol modulator, is the company's first FDA-approved medication. Corcept has discovered and owns exclusive rights to a large portfolio of proprietary compounds that modulate the effects of cortisol but not progesterone. The company holds United States and foreign intellectual property covering the composition of these selective cortisol modulators as well as the use of cortisol modulators, including mifepristone, to treat a wide variety of serious disorders.